Demonstrating that circulating proteins can reverse age‑related brain decline creates a viable pathway for novel therapeutics that may mitigate dementia and extend healthspan.
The Huberman Lab podcast features Dr. Tony Wyss‑Coray discussing how factors circulating in young blood can rejuvenate the aging brain and body. Using parabiosis—surgically joining the circulatory systems of young and old mice—his lab demonstrated that young‑derived proteins reactivate neural stem cells, dampen inflammation, and restore memory performance in aged rodents.
Key insights include the identification of thousands of age‑dependent plasma proteins, many of which decline sharply after youth. When plasma from young donors is injected into old mice, it reproduces the same stem‑cell activation and cognitive gains seen with young mouse blood. Translating this to humans, Wyss‑Coray’s company Alkaist tested human plasma fractions in mice and initiated small, placebo‑controlled trials in Alzheimer’s and Parkinson’s patients, reporting modest cognitive improvements.
Notable examples cited were a 500‑patient therapeutic plasma exchange study that showed significant benefits in Alzheimer’s patients, and a 40‑subject trial where epigenetic clocks indicated a measurable “younger” biological age after plasma treatment. Wyss‑Coray emphasizes the causal question—whether blood proteins drive aging or merely reflect it—and points to specific inflammatory factors whose neutralization improves cognition in mice.
The implications are profound: if the active components can be isolated, they could become precision anti‑aging drugs, offering a non‑invasive strategy to slow neurodegeneration and extend healthspan. However, larger, rigorously controlled clinical trials are needed before regulatory approval and widespread therapeutic use.
Comments
Want to join the conversation?
Loading comments...